



DAW
Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to: Mail Stop:
Amendment, Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 20th day of October 2005.
s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

JOHAN WILHELM STJERN SCHANTZ

Application No.: 10/723,140

Confirmation No.: 9449

Filed: November 25, 2003

For: PROSTAGLANDIN DERIVATIVES FOR THE
TREATMENT OF GLAUCOMA OR OCULAR
HYPERTENSION

Group Art Unit: 1626

Examiner: Rebecca L. Anderson

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. § 121

Mail Stop: Amendment
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This document responds to a Restriction Requirement mailed September 30, 2005, requiring a response by October 30, 2005. Accordingly this document has been filed timely. It is believed that no fee is due, however, authorization is hereby provided to charge, as stated under 37 C.F.R. §1.17, any fees required to Deposit Account No. 500329.

REMARKS

Claims 24-38 are pending in the present application. Claims 24-38 have been restricted into Groups I-XIV. Claims 25-28 and 30-38 are hereby withdrawn from consideration. Applicants reserve the rights to prosecute these withdrawn claims in the later filed divisional applications. Upon entry of this response to the restriction requirement, claims 24 and 29 are pending in the present application. Reconsideration of the restriction requirement is respectfully requested.

To expedite prosecution, Applicants hereby elect group I drawn to products classified in class 562 subclass 471 of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF_{2α}-isopropyl ester, without traverse.